Expanding Diagnostic Portfolio Immunostics offers a diverse range of diagnostic solutions across oncology, women's health, infectious diseases, respiratory conditions, and toxicology, presenting multiple entry points for collaboration or product integration with healthcare providers and laboratories.

Recent COVID-19 Innovations The launch of the AFIAS COVID-19 Ab test in 2020 highlights the company's capability to rapidly develop and deploy COVID-19 testing solutions, indicating opportunities to expand into emerging infectious disease markets and pandemic response services.

Strategic Acquisition Advantage Since its acquisition by Boditech Med in 2016, Immunostics has strengthened its market presence in the U.S., creating potential for sales growth through expanded distribution channels and enhanced brand recognition within the diagnostic sector.

Growth Potential in Mid-Sized Market With revenue ranging from one to ten million dollars and a dedicated workforce of up to 200 employees, Immunostics represents a viable target for customized sales solutions aimed at specialty healthcare institutions and laboratories seeking innovative diagnostic tools.

Technology Integration Opportunities Utilizing diverse tech platforms such as WordPress, PHP, and Google Tag Manager, Immunostics demonstrates a strong digital presence, opening avenues for digital marketing, eCommerce expansion, and ongoing tech-driven service enhancements to boost customer engagement.